Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes

Amy R Peck; Agnieszka K Witkiewicz; Chengbao Liu; Alexander C Klimowicz; Ginger A Stringer; Edward Pequignot; Boris Freydin; Ning Yang; Adam Ertel; Thai H Tran; Melanie A Girondo; Anne L Rosenberg; Jeffrey A Hooke; Albert J Kovatich; Craig D Shriver; David L Rimm; Anthony M Magliocco; Terry Hyslop; Hallgeir Rui

doi:10.1186/bcr3328

Table 3 Univariate and multivariate Cox regression survival analysis of breast cancer-specific survival (CSS) and time to recurrence (TTR) as a function of Nuc-Stat5a in breast cancer patients treated with antiestrogen monotherapy (Materials V and VI)

From: Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes

Material V CSS (n= 73)			Multivariate adjusted (Cox)		Univariate unadjusted (Cox)
Variable		n	Hazard ratio (95% CI)	Pvalue	Hazard ratio (95% CI)	Pvalue
Grade	1	17	1	-	1	-
	2	43	3.42 (0.42 to 27.87)	0.251	3.74 (0.46 to 30.52)	0.218
	3	13	2.60 (0.23 to 29.30)	0.438	3.32 (0.30 to 36.66)	0.327
Size	< 2 cm	40	1	-	1	-
	≥2 to ≥5 cm	33	4.29 (0.86 to 21.38)	0.075	5.79 (1.23 to 27.26)	0.026
Stat5a	Low (0)	9	4.19 (1.13 to 15.48)	0.032	6.73 (1.88 to 24.05)	0.003
	High (> 0)	64	1	-	1	-
Global test for PH assumption: χ²(3) = 1.67; P = 0.64.
Material V TTR ( n = 73)			Multivariate adjusted (Cox)		Univariate unadjusted (Cox)
Variable		n	Hazard ratio (95% CI)	P value	Hazard ratio (95% CI)	P value
Grade	1	17	1		1
	2	43	1.20 (0.30 to 4.81)	0.794	1.27 (0.32 to 5.04)	0.729
	3	13	1.59 (0.31 to 8.22)	0.581	1.87 (0.37 to 9.39)	0.448
Size	< 2 cm	40	1		1
	≥2 to ≥5 cm	33	1.63 (0.49 to 5.43)	0.429	2.24 (0.73 to 6.86)	0.158
Stat5a	Low (0)	9	4.27 (1.20 to 15.19)	0.025	5.08 (1.52 to 17.01)	0.008
	High (> 0)	64	1		1
Global test for PH assumption: χ²(3) = 1.47; P = 0.69.
Material VI CSS ( n = 55)			Multivariate adjusted (Cox)		Univariate unadjusted (Cox)
Variable		n	Hazard ratio (95% CI)	P value	Hazard ratio (95% CI)	P value
Grade	1	8	1	-	1	-
	2	28	3.48 (0.91 to 13.31)	0.068	1.11 (0.36 to 3.41)	0.855
	3	19	2.83 (0.65 to 12.28)	0.164	2.25 (0.73 to 6.91)	0.158
Size	< 2 cm	24	1	-	1	-
	2 to ≥5 cm	26	3.51 (1.26 to 9.74)	0.016	4.22 (1.76 to 10.13)	0.001
	≥5 cm	5	8.54 (1.92 to 37.94)	0.005	6.94 (2.01 to 24.00)	0.002
LN status	Neg	29	1	-	1	-
	Pos	26	4.72 (1.90 to 11.74)	< 0.001	4.30 (1.98 to 9.33)	< 0.001
ER/PR status	Neg	8	1	-	1	-
	Pos	47	0.73 (0.22 to 2.38)	0.597	0.37 (0.16 to 0.86)	0.021
Her2 status	Neg	48	1	-	1	-
	Pos	7	2.87 (0.92 to 8.96)	0.070	3.07 (1.23 to 7.63)	0.016
Stat5a	Low (< 1,454)	16	4.95 (1.87 to 13.06)	0.001	2.75 (1.33 to 5.69)	0.006
	High (≥1,454)	39	1	-	1	-
Global test for PH assumption: χ²(6) = 3.19; P = 0.78.
Material VI TTR ( n = 55)			Multivariate adjusted (Cox)		Univariate unadjusted (Cox)
Variable		n	Hazard ratio (95% CI)	P value	Hazard ratio (95% CI)	P value
Grade	1	8	1	-	1	-
	2	28	1.17 (0.37 to 3.72)	0.794	0.87 (0.31 to 2.41)	0.783
	3	19	1.24 (0.33 to 4.68)	0.746	1.98 (0.71 to 5.55)	0.191
Size	< 2 cm	24	1	-	1	-
	2 to ≥5 cm	26	3.38 (1.30 to 8.80)	0.013	3.75 (1.67 to 8.43)	0.001
	≥5 cm	5	8.17 (2.26 to 29.50)	0.001	6.91 (2.27 to 21.06)	< 0.001
LN status	Neg	29	1	-	1	-
	Pos	26	3.46 (1.57 to 7.64)	0.002	3.42 (1.67 to 7.01)	< 0.001
ER/PR status	Neg	8	1	-	1	-
	Pos	47	0.51 (0.17 to 1.48)	0.214	0.30 (0.13 to 0.68)	0.004
Her2 status	Neg	48	1	-	1	-
	Pos	7	3.35 (1.13 to 9.93)	0.029	3.06 (1.24 to 7.56)	0.015
Stat5a	Low (< 1,454)	16	2.14 (0.89 to 5.12)	0.087	2.15 (1.06 to 4.35)	0.033
	High (≥1,454)	39	1	-	1	-

Global test for PH assumption: χ²(6) = 4.67; P = 0.59. CI, confidence interval; ER/PR status, estrogen or progesterone receptor positive; HR, hazard ratio; LN status, lymph node status.

Back to article page